These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

119 related items for PubMed ID: 10819612

  • 1. Site of subcutaneous desferrioxamine injection is the initial site of post-transfusion urticaria in multi-transfused beta-thalassaemia major patients.
    Daar S, Ghosh K, Nirmala V.
    Clin Lab Haematol; 2000 Feb; 22(1):55-6. PubMed ID: 10819612
    [No Abstract] [Full Text] [Related]

  • 2. Subcutaneous desferrioxamine in homozygous beta-thalassaemia.
    Silvestroni E, Bianco I, Graziani B, Carboni C, Costantini S.
    Lancet; 1978 Nov 25; 2(8100):1149-50. PubMed ID: 82705
    [No Abstract] [Full Text] [Related]

  • 3. Growth failure and bone lesions due to desferrioxamine in thalassaemic patients.
    Caruso-Nicoletti M, Di Bella D, Pizzarelli G, Leonardi C, Sciuto C, Coco M, Di Gregorio F.
    J Pediatr Endocrinol Metab; 1998 Nov 25; 11 Suppl 3():957-60. PubMed ID: 10091171
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Cardiac function during iron chelation therapy in adult non-thalassaemic patients with transfusional iron overload.
    Jensen PD, Olsen N, Bagger JP, Jensen FT, Christensen T, Ellegaard J.
    Eur J Haematol; 1997 Oct 25; 59(4):221-30. PubMed ID: 9338620
    [Abstract] [Full Text] [Related]

  • 6. Early iron reduction programme for thalassaemia patients after bone marrow transplantation.
    Li CK, Lai DH, Shing MM, Chik KW, Lee V, Yuen PM.
    Bone Marrow Transplant; 2000 Mar 25; 25(6):653-6. PubMed ID: 10734300
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Survival and morbidity in transfusion-dependent thalassemic patients on subcutaneous desferrioxamine chelation. Nearly two decades of experience.
    Calleja EM, Shen JY, Lesser M, Grady RW, New MI, Giardina PJ.
    Ann N Y Acad Sci; 1998 Jun 30; 850():469-70. PubMed ID: 9668587
    [No Abstract] [Full Text] [Related]

  • 10. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload.
    Daar S, Pathare AV.
    Ann Hematol; 2006 May 30; 85(5):315-9. PubMed ID: 16450126
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Desferrioxamine-induced long bone changes in thalassaemic patients - radiographic features, prevalence and relations with growth.
    Chan YL, Li CK, Pang LM, Chik KW.
    Clin Radiol; 2000 Aug 30; 55(8):610-4. PubMed ID: 10964732
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Compliance and satisfaction with deferasirox (Exjade®) compared with deferoxamine in patients with transfusion-dependent beta-thalassemia.
    Haghpanah S, Zarei T, Zahedi Z, Karimi M.
    Hematology; 2014 Jun 30; 19(4):187-91. PubMed ID: 24074344
    [Abstract] [Full Text] [Related]

  • 15. Ocular toxicity of high-dose intravenous desferrioxamine.
    Davies SC, Marcus RE, Hungerford JL, Miller MH, Arden GB, Huehns ER.
    Lancet; 1983 Jul 23; 2(8343):181-4. PubMed ID: 6135026
    [Abstract] [Full Text] [Related]

  • 16. Beta-thalassaemia--the Johannesburg experience.
    Poole JE, Cohn RJ, Roode H, Spector I.
    S Afr Med J; 1989 Apr 15; 75(8):367-70. PubMed ID: 2652340
    [Abstract] [Full Text] [Related]

  • 17. [Evaluation of iron balance in homozygous beta-thalassemia subjects treated with desferrioxamine administered subcutaneously].
    Ferrara M, Galdo Capotorti M, Ponte G, Esposito L.
    Pediatria (Napoli); 1983 Apr 15; 91(4):371-7. PubMed ID: 6545400
    [No Abstract] [Full Text] [Related]

  • 18. Effect of different treatment regimes on linear growth and final height in beta-thalassaemia major.
    De Sanctis V, Katz M, Vullo C, Bagni B, Ughi M, Wonke B.
    Clin Endocrinol (Oxf); 1994 Jun 15; 40(6):791-8. PubMed ID: 8033371
    [Abstract] [Full Text] [Related]

  • 19. Audiologic and vestibular assessment in patients with β-thalassemia major receiving long-term transfusion therapy.
    Chao YH, Wu KH, Lin CY, Tsai MH, Peng CT, Wu HP, Lin CD.
    Pediatr Blood Cancer; 2013 Dec 15; 60(12):1963-6. PubMed ID: 23956204
    [Abstract] [Full Text] [Related]

  • 20. An alternative to continuous subcutaneous infusion of desferrioxamine in thalassaemic patients.
    Di Gregorio F, Romeo MA, Pizzarelli G, Aiello G, Russo G.
    Br J Haematol; 1997 Sep 15; 98(3):601-2. PubMed ID: 9332314
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.